Clinical Trial: Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07867626) titled 'Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML' on Sept. 25.

Brief Summary: To evaluate the 12-month relapse free survival with weekly Decitabine/cedazuridine plus Venetoclax in AML maintenance after achieving composite CR (CR, CRi, CRh)

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukaemia (AML)

Intervention: DRUG: Venetoclax, Decitabine/Cedaruridine

Patients who consent to the study will receive weekly Decitabine/Cedaruridine plus Venetoclax until intolerance or disease progression. Both Decitabine/Cedaruridine and Venetoclax are administered oral...